FDA Expands Approval of Vertex and CRISPR's Gene Therapy, Casgevy, to Include Children Aged 2 and Above
Expanding the Pediatric Patient Population to Enable Early Treatment Opportunities
The U.S. Food and Drug Administration (FDA) announced on July 1, 2026, that it has significantly expanded the approved age range for Casgevy (exagamglogene autotemcel), a gene-editing therapy co-developed by Vertex Pharmaceuticals and CRISPR Therapeutics, from 12 years and older to 2 years and above. This supplemental approval (sBLA) represents a significant milestone, offering infants and young children suffering from sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) the opportunity to address the underlying cause of their conditions early on. Specifically, by intervening during infancy, it may prevent recurrent vaso-occlusive crises (VOC) and long-term organ damage caused by continuous blood transfusions, potentially leading to a dramatic improvement in the long-term survival rate and quality of life for pediatric patients.
Efficacy Demonstrated Based on Clinical Data and Regulatory Science Achievements
This approval is based on clinical trial data conducted on pediatric patients aged 5 years and older, but under 12 years, which demonstrated the efficacy and safety of the drug to the regulatory authorities. In the pediatric SCD clinical trial, all 8 patients evaluated showed complete treatment efficacy, with no occurrence of severe vaso-occlusive crises (VOC) for at least 12 consecutive months after treatment. In the pediatric TDT clinical trial, 8 out of 9 patients evaluated achieved transfusion independence for at least 12 months. Based on this clinical data and the drug's mechanism of action, the FDA ultimately decided to extrapolate the efficacy to a very young pediatric population, aged 2 to 4 years, and granted final approval.
Safety and Market Expansion of Gene Editing Platform
Casgevy utilizes CRISPR/Cas9 gene-editing technology to target and edit the BCL11A gene in the patient's autologous CD34+ hematopoietic stem cells, thereby inhibiting the expression of fetal hemoglobin (HbF). This expanded indication for infants and young children has immediately broadened the addressable market for Casgevy, a high-cost gene therapy priced at approximately $2.2 million. However, managing potential side effects, such as mucositis and febrile neutropenia, caused by the mandatory high-dose busulfan pre-conditioning chemotherapy remains crucial. Furthermore, ongoing Phase 3 clinical trials, including CLIMB-141 and CLIMB-151, should continue to gather long-term safety data in pediatric patients.
Securing a Competitive Edge and Partnership Value
With this approval, Casgevy has secured a strong competitive advantage in the pediatric market compared to Bluebird Bio's Lyfgenia (lovotibeglogene autotemcel) and Zynteglo (betibeglogene autotemcel), which are indicated for patients aged 12 years and older and 4 years and older, respectively. Casgevy now has access to the largest pediatric patient population. Vertex and CRISPR Therapeutics are accelerating global commercialization through a partnership that splits profits and costs 60/40, and this pediatric approval will further solidify their long-term pipeline revenue growth and global leadership in the gene therapy field.
This approval allows Casgevy to secure an absolute advantage in the early market share competition by accessing a wider pediatric patient population than its competitors, Bluebird Bio's Lyfgenia (12 years and older) and Zynteglo (4 years and older). The global sickle cell disease (SCD) treatment market, estimated at $4.73 billion in 2026, is expected to grow with the introduction of gene therapies, reaching $20.47 billion in 2034, and this approval for Casgevy will accelerate this growth. Vertex and CRISPR are accelerating commercialization under a 60:40 profit-sharing agreement, with an upfront payment of $900 million and milestone payments of $200 million, to establish a long-term cash cow. If the long-term safety data from the Phase 3 CLIMB-141 and CLIMB-151 trials are confirmed, it will be a global milestone that lowers the regulatory barriers for gene-editing technologies.